Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Bionano Genomics, Inc is a diagnostics & research business based in the US. Bionano Genomics shares (BNGO) are listed on the NASDAQ and all prices are listed in US Dollars. Bionano Genomics employs 147 staff and has a trailing 12-month revenue of around USD0.00.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Active traders
52-week range | USD$0.3313 - USD$15.69 |
---|---|
50-day moving average | USD$8.352 |
200-day moving average | USD$4.971 |
Wall St. target price | USD$14.33 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-2.759 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | USD$8.5 million |
---|---|
Gross profit TTM | USD$2.8 million |
Return on assets TTM | -51.09% |
Return on equity TTM | -212.46% |
Profit margin | 0% |
Book value | $0.185 |
Market capitalisation | USD$1.6 billion |
TTM: trailing 12 months
There are currently 28.6 million Bionano Genomics shares held short by investors – that's known as Bionano Genomics's "short interest". This figure is 20.2% up from 23.8 million last month.
There are a few different ways that this level of interest in shorting Bionano Genomics shares can be evaluated.
Bionano Genomics's "short interest ratio" (SIR) is the quantity of Bionano Genomics shares currently shorted divided by the average quantity of Bionano Genomics shares traded daily (recently around 26.7 million). Bionano Genomics's SIR currently stands at 1.07. In other words for every 100,000 Bionano Genomics shares traded daily on the market, roughly 1070 shares are currently held short.
However Bionano Genomics's short interest can also be evaluated against the total number of Bionano Genomics shares, or, against the total number of tradable Bionano Genomics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bionano Genomics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Bionano Genomics shares in existence, roughly 100 shares are currently held short) or 0.1026% of the tradable shares (for every 100,000 tradable Bionano Genomics shares, roughly 103 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bionano Genomics.
Find out more about how you can short Bionano Genomics stock.
We're not expecting Bionano Genomics to pay a dividend over the next 12 months.
Over the last 12 months, Bionano Genomics's shares have ranged in value from as little as $0.3313 up to $15.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bionano Genomics's is 2.17. This would suggest that Bionano Genomics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.